University College London Hospital, NHS Foundation Trust

London WC1E 6AG

1 studies enrolling now · 9 studies all time

What they study most

Advanced Cholangiocarcinoma, Advanced Systemic Mastocytosis (AdvSM), Aggressive Systemic Mastocytosis (ASM), Colitis, Ulcerative, Diffuse Intrinsic Pontine Glioma, Endometrial Neoplasms, Ewing Sarcoma, FGFR2 Gene Rearrangements, Hereditary Thrombotic Thrombocytopenic Purpura (TTP), Mast Cell Leukemia (MCL), Medulloblastoma, Neuroblastoma

Studies at this site

• (Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis — Recruiting now
• Futibatinib Versus Gemcitabine-Cisplatin Chemotherapy as First-Line Treatment of Patients With Advanced Cholangiocarcinoma Harboring FGFR2 Gene Rearrangements — Stopped early
• Study Of Palbociclib Combined With Chemotherapy In Pediatric Patients With Recurrent/Refractory Solid Tumors — Running, not enrolling
• A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer (JAVELIN Ovarian 200) — Completed
• An Extension Study of IMR-687 in Adult Patients With Sickle Cell Anemia — Running, not enrolling
• A Study Evaluating the Efficacy and Safety of ST-0529 in Subjects With Moderately to Severely Active Ulcerative Colitis — Stopped early
• Phase 1 Dose Escalation, Single Dose Study to Assess Safety and Pharmacokinetics of BAX930 in Hereditary Thrombotic Thrombocytopenic Purpura (TTP) — Completed
• Avelumab in Previously Untreated Patients With Epithelial Ovarian Cancer (JAVELIN OVARIAN 100) — Stopped early
• A Study Of Two Dual PI3K/mTOR Inhibitors, PF-04691502 And PF-05212384 In Patients With Recurrent Endometrial Cancer — Stopped early